BIOMAT Database Logo BIOMAT Database Logo

Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. 2010

Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Division of Cardiology, St Michael's Hospital, University of Toronto, 30 Bond St., 6-050 Queen Wing, Toronto, ON, Canada. dorianp@smh.toronto.on.ca

The transvenous implantable cardioverter defibrillator (ICD) has emerged as the primary therapy for patients at high risk of life-threatening ventricular arrhythmias. A high number of ICD recipients will require subsequent adjunctive treatment with antiarrhythmic drugs (AADs). This review provides an overview of potential reasons for AAD initiation, candidates for treatment, current medical options, and possible drug-device interactions.

UI MeSH Term Description Entries
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017147 Defibrillators, Implantable Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes. Cardioverter-Defibrillators, Implantable,Implantable Cardioverter Defibrillator,Implantable Cardioverter-Defibrillators,Implantable Defibrillators,Cardioverter Defibrillator, Implantable,Cardioverter Defibrillators, Implantable,Cardioverter-Defibrillator, Implantable,Defibrillator, Implantable,Defibrillator, Implantable Cardioverter,Defibrillators, Implantable Cardioverter,Implantable Cardioverter Defibrillators,Implantable Cardioverter-Defibrillator,Implantable Defibrillator
D017180 Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias
D018579 Patient Selection Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols. Patient Recruitment,Research Subject Recruitment,Selection Criteria,Research Subject Selection,Selection for Treatment,Selection of Research Volunteers,Selection of Subjects,Criteria, Selection,Recruitment, Patient,Recruitment, Research Subject,Recruitments, Research Subject,Research Subject Recruitments,Research Subject Selections,Research Volunteers Selection,Research Volunteers Selections,Selection for Treatments,Selection, Patient,Selection, Research Subject,Selections, Research Subject,Subject Recruitment, Research,Subject Recruitments, Research,Subject Selection, Research,Subject Selections, Research,Subjects Selection,Subjects Selections,Treatment, Selection for,Treatments, Selection for,Volunteers Selection, Research

Related Publications

Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
January 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators.
January 1996, Current opinion in cardiology,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
January 2008, Circulation journal : official journal of the Japanese Circulation Society,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.
April 2014, American journal of cardiovascular drugs : drugs, devices, and other interventions,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Is there a role for antiarrhythmic drugs in patients with implantable defibrillators?
September 2006, Current cardiology reports,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
March 1999, The American journal of cardiology,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Reduction of antiarrhythmic drug use in patients receiving implantable cardioverter defibrillators.
January 1996, Pacing and clinical electrophysiology : PACE,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
July 2005, Pacing and clinical electrophysiology : PACE,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review.
February 2007, European heart journal,
Hugo Van Herendael, and Arnold Pinter, and Kamran Ahmad, and Victoria Korley, and Iqwal Mangat, and Paul Dorian
Patients with implantable cardioverter defibrillators (ICDs)
December 1999, Journal of cardiovascular electrophysiology,
Copied contents to your clipboard!